Research programme: CD8+ regulatory T cell therapy - TxCell

Drug Profile

Research programme: CD8+ regulatory T cell therapy - TxCell

Alternative Names: CAR engineered CD8+Treg cells - TxCell; CAR Tregs - TxCell

Latest Information Update: 03 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Center for Research in Transplantation and Immunology
  • Developer Center for Research in Transplantation and Immunology; Inserm Transfert; Nantes University Hospital; TxCell
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders; Inflammation; Multiple sclerosis; Transplant rejection

Most Recent Events

  • 21 Feb 2018 TxCell announces intention to submit CTA/IND to MHRA/USFDA in Q4 2018
  • 19 Jun 2017 TxCell and Lentigen Technology agree to manufacture HLA-A2 CAR lentiviral vector for the CAR-Treg product for Transplant rejection
  • 02 May 2017 TxCell and Inserm Transfert agree to co-develop CD8+ regulatory - T cell therapy for Transplant rejection and Multiple sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top